WEGOVY
LaunchNDAORALTABLET
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
4/8 — Partial
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WEGOVY (semaglutide) is an oral small-molecule GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities. It works by mimicking glucagon-like peptide-1, a hormone that regulates appetite and blood sugar, reducing hunger and promoting satiety. This represents Novo Nordisk's oral formulation entry into the high-growth weight-loss market dominated by injectable competitors.
$0.2MPart D
LaunchGrowing
12.5 years to LOEEarly-stage launch with zero competitive pressure creates high-impact career opportunities in brand-building, market development, and team expansion across commercial and medical functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
WEgovy Real World Assessment of Weight Loss in Korea
Started Nov 2025
500 enrolled
Obesity
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
Started May 2025
1,250 enrolled
Obesity
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
Started Mar 2025
408 enrolled
Obesity
A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea
Started Nov 2024
840 enrolled
Obesity and Overweight
Special Use - Results Surveillance on Long-term Use With Wegovy®
Started Jun 2024
1,071 enrolled
Obesity
Worked on WEGOVY at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.